Intra-mesenteric steroids for steroid-refractory graft-versus-host disease in pediatric patients: A safe option
Reports in the adult population have shown an approximately 50% response rate with few complications, making it a second-line management standard. As far as we know, this is the largest pediatric cohort reported in Latin America. Our findings suggest that intra-mesenteric steroid administration for managing hepatic and gastrointestinal graftversus-host disease may be considered an early adjuvant treatment in patients with steroidrefractory graft-versus-host disease.
Authors
- Ana M. Aristizábal
- Walter Mosquera (ORCID: https://orcid.org/0000-0002-4010-2103)
- Jaiber Gutiérrez (ORCID: https://orcid.org/0000-0002-0550-0923)
- Diego Medina (ORCID: https://orcid.org/0000-0002-1465-7957)
- Lina Paola Montaña-Jiménez (ORCID: https://orcid.org/0000-0002-0723-8842)
- Alexis A. Franco (ORCID: https://orcid.org/0000-0002-3173-6059)
- Eliana Manzi (ORCID: https://orcid.org/0000-0001-5577-970X)
- Ángela Devia (ORCID: https://orcid.org/0000-0003-1845-9082)
Institutions
- Fundación Valle del Lili (CO)
- Icesi University (CO)
Publication Details
- Journal
- Biomédica
- Published
- 2024-12-23
- DOI
- https://doi.org/10.7705/biomedica.7394
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00